ClinicalTrials.gg
CompletedNCT01350505Updated Feb 15, 2019Results posted

Toileting at Night in Older Adults: Light to Maximize Balance, Minimize Insomnia

An interventional study of White light exposure and Dim white light exposure in Falls, Balance and Insomnia, sponsored by VA Office of Research and Development. Completed at 1 site in United States. Open to participants aged 55 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-02-15.

Sponsored by VA Office of Research and Development · Not applicable, Interventional, and Basic science

Phase
Not applicable
Study type
Interventional
Enrollment
21
Ages
55 Years to 85 Years
Sex
All
01

Study summary

To examine the change in balance that occurs in older individuals when exposed to different colored lights at night.

02

Conditions studied

  • Falls
  • Balance
  • Insomnia
  • Aging

Keywords

  • Postural Balance
  • Sleep Initiation and Maintenance Disorders
03

In context

Sleep Initiation and Maintenance Disorders

1,930 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 612 are open to participants now.

This study's enrollment of 21 is below the median of 72 across 1,689 interventional studies indexed under Sleep Initiation and Maintenance Disorders.

Browse Sleep Initiation and Maintenance Disorders studies →

Lead sponsor

VA Office of Research and Development is the lead sponsor of 1,768 studies on the registry; 393 are open to participants now.

Of its 210 completed or terminated interventional studies of FDA-regulated products, 183 (87%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
55 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 55-85
  • Stable health
  • Normal color vision

Exclusion criteria

Exclusion Criteria:

  • Alcohol abuse
  • Depression
  • Sleep disorders
  • Smoking
  • Use of illegal drugs
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    All subjects

    13 minutes of light at night (2 hours after bedtime)

    Behavioral: White light exposure · Behavioral: Dim white light exposure · Behavioral: Very dim white light exposure · Behavioral: Dim orange light exposure

Interventions

  • BehavioralWhite light exposure

    \~200 lux of broad spectrum white light

  • BehavioralDim white light exposure

    \~28 lux of broad spectrum white light

  • BehavioralVery dim white light exposure

    \<0.5 lux of broad spectrum white light

  • BehavioralDim orange light exposure

    \~28 lux of orange light

06

What researchers measure

Primary outcomes

  1. Change in Balance

    Balance was assessed during a 13-minute nocturnal light exposure (4 different conditions) and differences between the conditions were assessed. To determine goodness of balance while walking, the variability in stride length (i.e., variance in stride-to-stride length) was calculated in each of the conditions. Increased variability in stride length is associated with increased risk of falling.

    Time frame: 13 minutes

07

Results

Posted Feb 15, 2019
Limitations and caveats
* Tested only at a single, approximate circadian phase * Did not have a large enough sample size to discriminate the effect of awakening out of different sleep stages or the impact of factors such as age, sex, and race

Participant flow

Participant flow — Overall Study
MilestoneLight Exposure
Started21
Completed17
Not completed4
Withdrew: Lost to follow-up4

Outcome measures

PrimaryChange in Balance

Balance was assessed during a 13-minute nocturnal light exposure (4 different conditions) and differences between the conditions were assessed. To determine goodness of balance while walking, the variability in stride length (i.e., variance in stride-to-stride length) was calculated in each of the conditions. Increased variability in stride length is associated with increased risk of falling.

Time frame:
13 minutes
Reported as:
Mean · %CV
Change in Balance
%CVLight Exposure
Very Dim White - Step Length6.66 ± 3.08
Dim White - Step Length5.34 ± 2.00
Dim Orange - Step Length5.62 ± 2.52
Room White - Step Length5.78 ± 2.87

Adverse events

Collected over Adverse event data were collected over 1 day. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Light Exposure0/21 (0%)0/21 (0%)0/21 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)Light Exposure
Mean64.7 ± 8.0
Sex: Female, Male
Sex: Female, Male(Participants)Light Exposure
Female11
Male10
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Light Exposure
Hispanic or Latino3
Not Hispanic or Latino18
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Light Exposure
American Indian or Alaska Native1
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American1
White15
More than one race2
Unknown or Not Reported1
Region of Enrollment
Region of Enrollment(participants)Light Exposure
United States21
Body Mass Index
Body Mass Index(kg/m²)Light Exposure
Mean26.9 ± 6.1
Baseline total sleep time
Baseline total sleep time(hours)Light Exposure
Mean7.32 ± .73
Baseline sleep efficiency
Baseline sleep efficiency(% of time in bed person is asleep)Light Exposure
Mean91.9 ± 5.6

5 further baseline measures are reported on the registry.

08

Study locations

1 site
  • VA Palo Alto Health Care System, Palo Alto, CA
    Palo Alto, California 94304-1290, United States
09

References and documents

Publications

  • McBean AL, Najjar RP, Schuchard RA, Hall CD, Wang CA, Ku B, Zeitzer JM. Standing Balance and Spatiotemporal Aspects of Gait Are Impaired Upon Nocturnal Awakening in Healthy Late Middle-Aged and Older Adults. J Clin Sleep Med. 2016 Nov 15;12(11):1477-1486. doi: 10.5664/jcsm.6270. PubMed 27448415 ↗

Study documents

  • Study protocol · Sep 26, 2018
  • Statistical analysis plan · Sep 26, 2018
  • Informed consent form · Aug 31, 2016

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: Yes — All relevant summary data is presented in a publication under review. Anonymized, individual participant data would be made available upon request and completion of necessary documentation.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 15, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01350505
Responsible party
Sponsor
First posted
May 9, 2011
Start date
Oct 15, 2013
Primary completion
Jan 31, 2017
Completion
Jun 30, 2017
Results posted
Feb 15, 2019
Last update
Feb 15, 2019

Study contacts

Jamie M Zeitzer, PhD
principal investigator · VA Palo Alto Health Care System, Palo Alto, CA

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion